The Fight for the Cure Golf tournament on May 17th was a fantastic success! Find out how many funds were raised for MAP research, and what Human Para is doing next. a huge THANK YOU to the Joly family and all of our volunteers who made this event a success.
The American College of Gastroenterology (ACG) recently released the 2018 Guidelines for the treatment of Crohn’s Disease (CD). Such guidelines can profoundly influence how practitioners treat CD and how younger physicians perceive CD pathophysiology. It is therefore intensely disappointing to read the ACG’s mistaken and blatantly unsupported conclusions in regard to mycobacteria and Atypical Mycobacterial Antibiotic Therapy (AMAT) for CD.
Human Para is pleased to announce our 2018 Conference: Mycobacterial Implications in Crohn’s and Chronic Inflammatory Diseases. On September 21 & 22, 2018, a group of dedicated researchers will bring their experience and expertise to Berkeley, California for a two-day conference. Featuring presenters and experts from across the globe, this conference has been specifically designed to explore the role that mycobacteria, particularly Mycobacterium avium spp. paratuberculosis (MAP), may play in Crohn’s disease, Type 1 diabetes, multiple sclerosis and other chronic conditions.
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Read all the latest news and research about Mycobacterium avium subsp.paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT and other therapies. Enjoy!
The specific carbohydrate diet (SCD) is a strict grain-free, lactose-free and sucrose-free diet therapy.
Until recently the link between diet, gut bacteria and disease had been ignored by mainstream medicine. Only in the last decade, as the human microbiome took center stage in scientific research and attention to diet therapies began to grow, the SCD gained the attention of the medical community. Lately it has been investigated in multiple studies as a legitimate medical option for managing disease.
People with digestive diseases, such as Crohn’s disease, ulcerative colitis, IBS and SIBO, may benefit from supplementation with Oil of Oregano due to it’s anti-microbial and anti-inflammatory properties. This article discusses the active ingredients of oregano, looks at research using oregano in digestive diseases and answers questions about the different forms and preparations of oregano.